AF
HEPA

Advisornet Financial’s Hepion Pharmaceuticals HEPA Stock Holding History

Advisornet Financial’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$42 – 2082
2024
Q3 		$42 Sell
1
-1
-50% -$40 ﹤0.01% 2170
2024
Q2 		$90 Sell
2
-2
-50% -$148 ﹤0.01% 2057
2024
Q1 		$438 Buy
+4
New +$460 ﹤0.01% 1898

Other funds holding HEPA

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Advisornet Financial's HEPA Position: Q4 2024 in Review

Advisornet Financial sold out of Hepion Pharmaceuticals (HEPA) in Q4 2024, closing a stake of 1 share — an estimated $42 sold.

Advisornet Financial first reported a position in HEPA in Q1 2024 and held it in 3 quarters. The position peaked at $438 in Q1 2024. 16 funds tracked by Wall St. Rank hold HEPA as of Q4 2024.

  • Advisornet Financial reported no remaining Hepion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Advisornet Financial sold 1 Hepion Pharmaceuticals share in Q4 2024, an estimated $42.
  • Advisornet Financial first reported a position in Hepion Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Advisornet Financial's Hepion Pharmaceuticals position peaked at $438 in Q1 2024.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q4 2024.

Based on Advisornet Financial's 13F filing for Q4 2024, filed 13 Jan 2025.